Correlation of overall survival (OS) in patients (pts) with inoperable hepatocellular carcinoma (iHCC) receiving tivozanib (TIVO) with baseline performance status

Lee, SS; Krishnamurthi, SS; Miller, A; Estfan, BN; Wang, C; Frazer, A

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):